Benzoxazinones as PPARγ Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model

Journal of Medicinal Chemistry

Volumn 47, Issue 1, 2004, Pages 196-209

  Rybczynski, Philip J ^a   Zeck, Roxanne E ^a   Dudash Jr , Joseph ^a   Combs, Donald W ^a   Burris, Thomas P ^a,b   Yang, Maria ^a   Osborne, Melville C ^a   Chen, Xiaoli ^a   Demarest, Keith T ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (4 (4 METHOXYBUTYL) 3 OXO 3,4 DIHYDRO 2H BENZ[1,4]OXAZIN 2 YL)ETHOXY]PHENYLACETIC ACID; 2 [2 (4 HEXYL 3 OXO 3,4 DIHYDRO 2H BENZ[1,4]OXAZIN 2 YL)ETHOXY]PHENYLACETIC ACID; BENZOXAZINONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; UNCLASSIFIED DRUG; AMIDE; CELL RECEPTOR; CYTOCHROME P450; OXAZINE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIRALITY; CONTROLLED STUDY; DISEASE SIMULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HUMAN CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; LIVER MICROSOME; METABOLISM; RAT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMIDES; ANIMALS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, TYPE 2; DRUG STABILITY; FEMALE; HUMANS; MICE; MICROSOMES, LIVER; OXAZINES; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 0347361637     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0301888     Document Type: Article

References (40)

1. (a) Picard, F.; Auwerx, J. PPARγ and Glucose Homeostasis. Annu. Rev. Nutr. 2002, 22, 167-197.
2. (b) Demer, L. Adipose Rex: Fat and Fats That Rule Differentiation. Circ. Res. 2002, 90, 241-243.
3. Mukherjee, R. PPARs: Versatile Targets for Future Therapy for Obesity, Diabetes and Cardiovascular Disease. Drug News Perspect. 2002, 15, 261-267.
4. Berger, J.; Moller, D. E. The Mechanism of Action of PPARs. Annu. Rev. Med. 2002, 53, 409-435.
5. Rosen, E. D.; Hsu, C.-H.; Wang, X.; Sakai, S.; Freeman, M. W.; Gonzalez, F. J.; Spiegelman, B. M. C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes Dev. 2002, 16, 22-26.
6. Walczak, R.; Tontonoz, P. PPARadigms and PPARadoxes: expanding the roles for PPARγ in the control of lipid metabolism. J. Lipid Res. 2002, 43, 177-186.
7. Yamauchi, T.; Kamon, J.; Waki, H.; Murakami, K.; Motojima, K.; Komeda, K.; Ide, T.; Kubota, N.; Terauchi, Y.; Tobe, K.; Miki, H.; Tsuchida, A.; Akanuma, Y.; Nagai, R.; Kimura, S.; Kadowaki, T. The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance. J. Biol. Chem. 2001, 276, 41245-41254.
8. Guan, H.-P.; Li, Y.; Jensen, M. V.; Newgard, C. B.; Steppan, C. M.; Lazar, M. A. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med. 2002, 8, 1122-1128.
9. Yamauchi, T.; Waki, H.; Kamon, J.; Murakami, K.; Motojima, K.; Komeda, K.; Miki, H.; Kubota, N.; Terauchi, Y.; Tsuchida, A.; Tsuboyama-Kasaoka, N.; Yamauchi, N.; Ide, T.; Hori, W.; Kato, S.; Fukayama, M.; Akanuma, Y.; Ezaki, O. ; Itai, A.; Nagai, R.; Kimura, S.; Tobe, K.; Kagechika, H.; Shudo, K.; Kadowaki, T. Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J. Clin. Invest. 2001, 108, 1001-1013.
10. Corton, J. C.; Anderson, S. P.; Stauber, A. Central Role of Peroxisome-Proliferator-Activated Receptors in the Actions of Peroxisome Proliferators. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 491-518.
11. 12,14-Prostaglandin J2 Is a Ligand for the Adipocyte Determination Factor PPARγ. Cell 1995, 83, 803-812.
12. (b) Kliewer, S. A.; Lenhard, J. M.; Willson, T. M.; Patel, I.; Morris, D. C.; Lehmann, J. M. A Prostaglandin J2 Metabolite Binds Peroxisome Proliferator-Activated Receptor γ and Promotes Adipocyte Differentiation. Cell 1995, 83, 813-819.
13. (c) Nosjean, O.; Boutin, J. A. Natural ligands of PPARγ: Are prostaglandin J2 derivatives really playing the part? Cell. Signaling 2002, 14, 573-583.
14. Hwang, B. Y.; Lee, J.-H.; Nam, J. B.; Kim, H. S.; Hong, Y. S.; Lee, J. J. Two New Furanoditerpenes from Saururus chinenesis and Their Effects on the Activation of Peroxisome Proliferator-Activated Receptor γ. J. Nat. Prod. 2002, 65, 616-617.
15. (a) Patel, M.; Rybczynski, P. J. Treatment of noninsulin-dependent diabetes mellitus. Exp. Opin. Invest. Drugs 2003, 12, 623-633.
16. (b) Leff, T.; Reed, J. E. The Antidiabetic PPARγ Ligands: An Update on Compounds in Development. Curr. Med. Chem.-Immunol., Endocr., Metab. Agents 2002, 2, 33-47.
17. (c) Jones, A. B. Peroxisome Proliferator-Activated Recpetor (PPAR) Modulators: Diabetes and Beyond. Med. Res. Rev. 2001, 21, 540-552.
18. (d) Rocchi, S.; Picard, F.; Vamecq, J.; Gelman, L.; Potier, N.; Zeyer, D.; Dubuquoy, L.; Bac, P.; Champy, M.-F.; Plunket, K. D.; Leesnitzer, L. M.; Blanchard, S. G.; Desreumaux, P.; Moras, D.; Renaud, J.-P.; Auwerx, J. A Unique PPARγ Ligand with Potent Insulin-Sensitizing yet Weak Adipogenic Activity. Mol. Cell 2001, 8, 737-747.
19. (a) Wagstaff, A. J.; Goa, K. L. Rosiglitazone. A Review of its Use in the Management of Type 2 Diabetes Mellitus. Drugs 2002, 62, 1805-1837.
20. (b) Diamant, M.; Heine, R. J. Thiazolidinediones in Type 2 Diabetes Mellitus. Drugs 2003, 63, 1373-1405.
21. (a) Chilcott, J.; Tappenden, P.; Jones, M. L.; Wight, J. P. A Systematic Review of the Clinical Effectiveness of Pioglitazone in the Treatment of Type 2 Diabetes Mellitius. Clin. Ther. 2001, 23, 1792-1823.
22. (b) Grossman, L. D. New Solutions for Type 2 Diabetes Mellitus. PharmacoEconomics 2002, 20, 1-9.
23. (a) Henke, B. R.; Blanchard, S. G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Kliewer, S. A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J. F.; Mook, R. A., Jr.; Noble, S. A.; Oliver, W., Jr.; Parks, D. J.; Plunket, K. D., Szewezyk, J. R.; Willson, T. M. N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents. J. Med. Chem. 1998, 41, 5020-5036.
24. (b) Collins, J. L.; Blanchard, S. G.; Boswell, G. E.; Charifson, P. S.; Cobb, J. E.; Henke, B. R.; Hull-Ryde, E. A.; Kazmierski, W. M.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J.; Lenhard, J. M.; Orband-Miller, L. A.; Gray-Nunez, Y.; Parks, D. J.; Plunkett, K. D.; Tong, W.-Q. N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 2. Structure-Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety. J. Med. Chem. 1998, 41, 5037-5054.
25. (c) Cobb, J. E.; Blanchard, S. G.; Boswell, E. G.; Brown, K. K.; Charifson, P. S.; Cooper, J. P.; Collins, J. L.; Dezube, M.; Henke, B. R.; Hull-Ryde, E. A.; Lake, D. H.; Lenhard, J. M.; Oliver, W., Jr.; Oplinger, J.; Pentti, M.; Parks, D. J.; Plunket, K. D.; Tong, W.-Q. N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent. J. Med. Chem. 1998, 41, 5055-5069.
26. (d) Sorbera, L. A.; Leeson, P. A.; Martin, L.; Castaner, J. Farglitazar. Antidiabetic PPARγ agonist. Drugs Future 2001, 26, 354-363.
27. Nomura, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; Awano, K. (3-Substituted Benzyl)-thiazolidine-2,4-diones as Structurally New Antihyperglycemic Agents. Bioorg. Med. Chem. Lett. 1999, 9, 533-538.
28. (a) Shinkai, H.; Onogi, S.; Tanaka, M.; Shibata, T.; Iwao, M.; Wakitani, K.; Uchida, I. Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl Compounds as Hypoglycemic Agents. J. Med. Chem. 1998, 41, 1927-1933.
29. (b) Shinkai, H. The isoxazolidine-3,5-dione hypoglycemic agent JTT-501 and other nonthiazolidinedione insulin sensitizers. Drugs Future 1999, 24, 893-898.
30. Lohray, B. B.; Lohray, V. B.; Bajji, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R. K.; Misra, P.; Juluri, S.; Mamidi, N. V. S. R.; Rajagopalan, R. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxylphenyl]-2-ethoxypropionic Acid [(-)DRF2725]: A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating Activity. J. Med. Chem. 2001, 44, 2675-2678.
31. Ljung, B.; Bamberg, K.; Dahllof, B.; Kjellstedt, A.; Oakes, N. D.; Ostling, J.; Svensson, L.; Camejo, G. AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res. 2002, 43, 1855-1863.
32. Sorbera, L. A.; Castaner, J.; Del Fresno, M.; Silvestre, J. Netoglitazone. Drugs Future 2002, 27, 132-139.
33. Rybczynski, P. J.; Zeck, R. E.; Combs, D. W.; Turchi, I.; Burris, T. P.; Xu, J. X.; Yang, M.; Demarest, K. T. Benzoxazinones as PPARγ Agonists. 1. SAR of the Three Aromatic Regions. Bioorg. Med. Chem. Lett. 2003, 13, 2359-2362.
34. (a) Burris, T. P.; Rybczynski, P. J. Preparation of benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment. WO01/87860, 2001; Chem. Abstr. 2001, 135, 371750.
35. (b) Burris, T. P.; Demarest, K. T.; Combs, D. W.; Rybczynski, P. J.; Turchi, I. J. Preparation of benzoxazinones as peroxisome proliferator activated receptor gamma modulators. WO01/87861; Chem. Abstr. 2001, 135, 371751.
36. (c) Burris, T. P.; Combs, D. W.; Rybczynski, P. J. Biologically active 4H-benzo[1,4]oxazin-3-ones useful as PPARγ agonists or antagonists. WO01/87862; Chem. Abstr. 2002, 136, 5997.
37. (d) Burris, T. P.; Combs, D. W.; Rybczynski, P. J.; Dudash, J., Jr. Biologically active 4H-benzo[1,4]oxazin-3-ones useful as PPARγ agonists or antagonists. US2003083329 A1; Chem. Abstr. 2003, 138, 368896.
38. Burris, T. P.; Pelton, P. D.; Zhou, L.; Osborne, M. C.; Cryan, E.; Demarest, K. T. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. Mol. Endocrinol. 1999, 13, 410-417.
39. Silverman, R. B. The Organic Chemistry of Drug Design and Drug Action; Academic Press: New York, 1992; pp 16-17.
40. 2 for receptor binding studies.